Additional Analysis of the Secondary End Point of Biochemical Recurrence Rate in a Phase 3 Trial (CS21) Comparing Degarelix 80 mg Versus Leuprolide in Prostate Cancer Patients Segmented by Baseline Characteristics

European Urology

Volumn 57, Issue 5, 2010, Pages 836-842

  Tombal, Bertrand ^a   Miller, Kurt ^b   Boccon Gibod, Laurent ^c   Schröder, Fritz ^d   Shore, Neal ^e   Crawford, E David ^f   Moul, Judd ^g   Jensen, Jens Kristian ^h   Kold Olesen, Tine ⁱ   Persson, Bo Eric ^j  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c BICHAT HOSPITAL   (France)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e Carolina Urologic Research Center   (United States)

^f UNIVERSITY OF COLORADO   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h Ferring Phamaceuticals   (Denmark)

ⁱ Ferring Pharmaceuticals Inc USA   (United States)

^j Ferring Pharmaceuticals AS   (Denmark)

more..

Author keywords

Degarelix; GnRH receptor antagonist; GnRH receptor blocker; Leuprolide; Prostate cancer; PSA

Indexed keywords

DEGARELIX; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE-FREE SURVIVAL; GONADOTROPIN-RELEASING HORMONE; HUMANS; LEUPROLIDE; MALE; NEOPLASM RECURRENCE, LOCAL; OLIGOPEPTIDES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 77949653652     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.11.029     Document Type: Article

References (30)

1. Van Poppel H., and Nilsson S. Testosterone surge: rationale for gonadotropin-releasing hormone blockers?. Urology 71 (2008) 1001-1006
2. Zinner N.R., Bidair M., Centeno A., and Tomera K. Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: results of a randomized open-label trial. Urology 64 (2004) 1177-1181
3. Lepor H. Comparison of single-agent androgen suppression for advanced prostate cancer. Rev Urol 7 Suppl 5 (2005) S3-12
4. Gittelman M., Pommerville P.J., Persson B.E., Jensen J.K., and Kold Olesen T. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. J Urol 180 (2008) 1986-1992
5. Van Poppel H., Tombal B., de la Rosette J.J., Persson B.-E., Jensen J.-K., and Kold Olesen T. Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker-results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. Eur Urol 54 (2008) 805-815
6. Fleming M.T., Morris M.J., Heller G., and Scher H.I. Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials. Nat Clin Pract Oncol 3 (2006) 658-667
7. Lilja H., Ulmert D., and Vickers A.J. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 8 (2008) 268-278
8. Williams S.G., Duchesne G.M., Millar J.L., and Pratt G.R. Both pretreatment prostate-specific antigen level and posttreatment biochemical failure are independent predictors of overall survival after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 60 (2004) 1082-1087
9. Hussain M., Tangen C.M., Higano C., et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 24 (2006) 3984-3990
10. Hussain M., Goldman B., Tangen C., et al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol 27 (2009) 2450-2456
11. Klotz L., Boccon-Gibod L., Shore N.D., et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 102 (2008) 1531-1538
12. Swindle P.W., Kattan M.W., and Scardino P.T. Markers and meaning of primary treatment failure. Urol Clin North Am 30 (2003) 377-401
13. Newling D., Carroll K., and Morris T. Is prostate-specific antigen progression a surrogate for objective clinical progression in early prostate cancer?. J Clin Oncol 22 14S (2004) abstract 4652
14. Cooper E.H., Armitage T.G., Robinson M.R., et al. Prostatic specific antigen and the prediction of prognosis in metastatic prostatic cancer. Cancer 66 (1990) 1025-1028
15. Collette L., Burzykowski T., Carroll K.J., Newling D., Morris T., and Schroder F.H. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. J Clin Oncol 23 (2005) 6139-6148
16. Miller J.I., Ahmann F.R., Drach G.W., Emerson S.S., and Bottaccini M.R. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J Urol 147 (1992) 956-961
17. Newling D.W., Denis L., and Vermeylen K. Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer-Genitourinary Group Study 30853. Cancer 72 (1993) 3793-3798
18. Collette L., De Reijke T.M., Schröder F.H., and members of the EORTC Genito-Urinary Group. Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892). Eur Urol 44 (2003) 182-189
19. Wiebe E., Rodrigues G., Lock M., D'Souza D., and Stitt L. Outcome analysis of prostate cancer patients with pre-treatment PSA greater than 50 ng/ml. Can J Urol 15 (2008) 4078-4083
20. Haukaas S.A., Halvorsen O.J., Daehlin L., Hostmark J., and Akslen L.A. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?. BJU Int 97 (2006) 51-55
21. Stock R.G., and Stone N.N. The effect of prognostic factors on therapeutic outcome following transperineal prostate brachytherapy. Semin Surg Oncol 13 (1997) 454-460
22. D'Amico A.V., Chen M.H., Catalona W.J., Sun L., Roehl K.A., and Moul J.W. Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors. Cancer 110 (2007) 56-61
23. Proust-Lima C., Taylor J.M., Williams S.G., et al. Determinants of change in prostate-specific antigen over time and its association with recurrence after external beam radiation therapy for prostate cancer in five large cohorts. Int J Radiat Oncol Biol Phys 72 (2008) 782-791
24. Kupelian P.A., Katcher J., Levin H.S., and Klein E.A. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys 37 (1997) 1043-1052
25. Morote J., Orsola A., Planas J., et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol 178 (2007) 1290-1295
26. Angelucci C., Lama G., Iacopino F., et al. GnRH receptor expression in human prostate cancer cells is affected by hormones and growth factors. Endocrine 36 (2009) 87-97
27. Porter A.T., and Ben-Josef E. Humoral mechanisms in prostate cancer: a role for FSH. Urol Oncol 6 (2001) 131-138
28. Scher H.I., Halabi S., Tannock I., et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26 (2008) 1148-1159
29. Beer T.M., Garzotto M., Eilers K.M., and Lemmon D. Phase II study of abarelix depot for androgen independent prostate cancer progression during gonadotropin-releasing hormone agonist therapy. J Urol 169 (2003) 1738-1741
30. Beer T.M., Garzotto M., Eilers K.M., Lemmon D., and Wersinger E.M. Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing after orchiectomy. Urology 63 (2004) 342-347